INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2022

GLP-1 receptor agonist use was linked to increased risks of gallbladder and biliary diseases in a meta-analysis of randomized clinical trials.

A systematic review and meta-analysis of 76 RCTs with 103,371 patients examined the risk of gallbladder or biliary diseases associated with GLP-1 receptor agonists compared to placebo or non-GLP-1 RA drugs. Randomization to GLP-1 RA treatment was associated with increased risk of gallbladder or biliary diseases (RR 1.37; 95% CI, 1.23-1.52), including cholelithiasis (RR 1.27; 95% CI, 1.10-1.47), cholecystitis (RR 1.36; 95% CI, 1.14-1.62), and biliary disease (RR 1.55; 95% CI, 1.08-2.22). Risks were higher in trials for weight loss (RR 2.29; 95% CI, 1.64-3.18) than for type 2 diabetes or other diseases (RR 1.27; 95% CI, 1.14-1.43), as well as with higher doses (RR 1.56 vs 0.99 for lower doses) and longer durations of use (RR 1.40 vs 0.79 for shorter duration).

Study type
Systematic review and meta-analysis of randomized clinical trials
Who was studied
103,371 adult patients across 76 RCTs (mean age 57.8 years; 40.5% women)
What was measured
Composite of gallbladder or biliary diseases, biliary diseases, biliary cancer, cholecystectomy, cholecystitis, and cholelithiasis

THE PAPER

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. JAMA Intern Med, 2022.

PubMed 35344001 ↗DOI 10.1016/s2213-8587(21)00174-1 ↗

Diabetes & blood sugarGut & microbiomeWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.